Inozyme Pharma, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2019 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Inozyme Pharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2019 to Q1 2025.
  • Inozyme Pharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2025 was $1.86M, a 9.82% increase year-over-year.
  • Inozyme Pharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2025 was $8.11M, a 22.2% increase year-over-year.
  • Inozyme Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $7.95M, a 12.9% increase from 2023.
  • Inozyme Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7.04M, a 8.61% decline from 2022.
  • Inozyme Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7.7M, a 6.94% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $8.11M $1.86M +$166K +9.82% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $7.95M $1.97M +$298K +17.8% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-10
Q3 2024 $7.65M $2.13M +$454K +27.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $7.19M $2.16M +$557K +34.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $6.64M $1.69M -$401K -19.2% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14
Q4 2023 $7.04M $1.67M -$241K -12.6% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-10
Q3 2023 $7.28M $1.67M -$177K -9.57% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $7.46M $1.6M -$585K -26.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $8.04M $2.09M +$340K +19.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $7.7M $1.91M -$144K -7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-12
Q3 2022 $7.84M $1.85M +$97K +5.54% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $7.75M $2.19M +$372K +20.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $7.38M $1.75M +$175K +11.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $7.2M $2.06M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 $1.75M +$966K +123% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $1.81M +$1.69M +1411% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $1.58M +$1.45M +1122% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q3 2020 $786K +$679K +635% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $120K +$80K +200% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $129K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q3 2019 $107K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $40K Apr 1, 2019 Jun 30, 2019 10-Q 2020-09-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.